Soleno Therapeutics found using ticker (SLNO) now have 3 analysts in total covering the stock. The consensus rating is ‘Strong_Buy’. The target price ranges between 9 and 8 calculating the mean target price we have 8.67. With the stocks previous close at 1.95 this would indicate that there is a potential upside of 344.6%. The 50 day MA is 1.94 and the 200 moving average now moves to 1.95. The company has a market cap of $154m. You can visit the company’s website by visiting: http://soleno.life
Soleno Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia and changed its name to Soleno Therapeutics in May 2017. Soleno Therapeutics was incorporated in 1999 and is headquartered in Redwood City, California.